Pharmetrix Corporation

Judy M Mohr

Richard W Baker

Lisa A Nakaji

The invention is directed to a patch for the transdermal delivery of the racemic form or the active enantiomer of the analgesic ketorolac. The transdermal patch is capable of delivering therapeutically effective doses of the drug for a period of 12 hours or more. The patch is capable of delivering the racemate of ketorolac at a flux rate of 40 .mu.g/cm.sup.2 .multidot.hr or more, and of the active enantiomer at a flux rate of 20 .mu.g/cm.sup.2 .multidot.hr or more.

Liquid reservoir transdermal patch for the administration of ketorolac

The invention provides for the transdermal delivery of the active enantiomer of the analgesic ketorolac. Transdermal patches according to the invention are capable of delivering (-) ketorolac to a patient at therapeutically effective levels, at a flux rate of 20 .mu.g/cm.sup.2.hr or more. Patches for use in the present invention may be adhesive matrix, monolithic matrix, or liquid reservoir transdermal patches.

Growing community of inventors

Menlo Park, CA, United States of America

Judy M Mohr